.STUDY HIGHLIGHT.16 October 2024. In the NIAGARA hearing, the addition of perioperative durvalumab to conventional therapy for muscle-invasive bladder cancer enhanced event-free and also overall survival, denoting a brand-new therapy choice for this condition.